Friday 6 November 2026
Export DHR’s income statement to Excel — free account
Danaher Corporation
DHR Healthcare Diagnostics & Research
Danaher Corporation’s revenue for fiscal 2025 (year ended December 2025) was $24.6 billion, up 2.90% from fiscal 2024.
- Revenue
- +8.28%
- EPS
- +36.7%
- Free cash flow
- +19.1%
- Total debt
- +44.9%
Quarter to September 2026, against a year earlier
229.63
3.29
+1.45%
Follow DHR
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
45.15 | 36.53 | 33.71 | 36.20 |
P/S ratio |
6.64 | 5.42 | 5.35 | 6.09 | |
P/FCF ratio |
30.82 | 25.24 | 24.48 | 27.11 | |
P/Operating CF |
77.07 | 101.53 | 87.58 | 82.68 | |
P/B ratio |
3.11 | 2.53 | 2.55 | 2.91 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
7.20 | 5.90 | 6.18 | 6.82 | |
EV/EBITDA |
24.79 | 20.17 | 20.14 | 21.89 | |
EV/Operating CF |
27.58 | 22.69 | 23.38 | 25.46 | |
EV/FCF |
33.43 | 27.47 | 28.26 | 30.37 | |
Quick Ratio |
1.25 | 1.28 | 1.03 | 1.08 | |
Current Ratio |
1.87 | 1.87 | 1.65 | 1.63 | |
Net Debt/EBITDA |
6.49 | 6.02 | 11.35 | 9.12 | |
Debt/Assets |
22.06% | 21.02% | 27.23% | 26.14% | |
Debt/Equity |
0.35 | 0.33 | 0.48 | 0.45 | |
Asset Turnover |
0.31 | 0.30 | 0.29 | 0.30 | |
Operating CF/Net income |
1.77 | 1.28 | 1.76 | 1.53 | |
Capex/Depreciation |
(0.56) | (0.38) | (0.38) | (0.32) | |
Interest Coverage |
27.31 | 21.33 | 10.53 | 9.22 | |
Research and Development Expense of Revenue |
6.41% | 6.50% | 6.58% | 6.61% | |
Selling, General and Administrative Expense of Revenue |
29.63% | 31.26% | 33.07% | 32.94% | |
Intangible Assets out of Total Assets |
0.73 | 0.72 | 0.74 | 0.73 | |
Share Based Compensation of Revenue |
0.92% | 0.97% | 1.48% | 1.75% | |
Graham Net Nets |
(0.11) | (0.12) | (0.20) | (0.16) | |
Graham Number |
91.70 | 93.47 | 97.36 | 102.44 | |
Earnings Yield |
2.21% | 2.74% | 2.97% | 2.76% | |
Free Cash Flow Yield |
3.24% | 3.96% | 4.09% | 3.69% | |
Revenue per Share |
9.59 | 8.41 | 8.88 | 9.31 | |
Operating CF per Share |
2.97 | 1.87 | 2.18 | 2.68 | |
Capex per Share |
(0.49) | (0.33) | (0.38) | (0.36) | |
Free Cash Flow per Share |
2.48 | 1.53 | 1.79 | 2.32 | |
Cash per Share |
6.48 | 8.05 | 6.16 | 8.07 | |
Shareholders Equity per Share |
73.72 | 74.81 | 74.57 | 76.20 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
73.72 | 74.81 | 74.57 | 76.20 | |
Free Cash Flow |
1,769.00 | 1,085.00 | 1,265.00 | 1,632.00 | |
Working Capital |
5,949.00 | 6,475.00 | 5,276.00 | 5,737.00 | |
Capital Expenditures |
(348.00) | (237.00) | (269.00) | (254.00) | |
Net Current Asset Value |
(18,167.00) | (16,652.00) | (26,394.00) | (24,861.00) | |
EV/EBIT |
37.73 | 30.69 | 30.26 | 33.47 | |
Capex to Sales |
0.05 | 0.04 | 0.04 | 0.04 | |
Price to Operating Income |
34.79 | 28.20 | 26.20 | 29.88 | |
| Other line items | |||||
Average Receivables |
3,725.00 | 3,662.50 | 3,764.50 | 3,940.50 | |
Average Payables |
1,798.50 | 1,756.00 | 1,773.50 | 1,720.00 | |
Average Inventory |
2,409.50 | 2,570.00 | 2,974.50 | 2,904.00 | |
Average Assets |
80,503.00 | 81,330.00 | 86,993.50 | 86,589.00 | |
Average Common Equity |
51,045.50 | 51,907.00 | 52,467.00 | 52,356.50 |
Columns are period end dates · fundamentals updated 2 Nov 2026